Login to Your Account



Depomed's Proquin XR Wins FDA Approval As Treatment For UTIs

By Aaron Lorenzo


Monday, May 23, 2005
Shares in Depomed Inc. on Friday gained nearly 10 percent on news that the FDA approved Proquin XR, a once-daily, extended-release formulation of ciprofloxacin hydrochloride that the specialty pharmaceutical company soon plans to partner. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription